[Form 4] BioCardia, Inc. Warrant Insider Trading Activity

Rhea-AI Filing Summary

Peter Altman, who serves as President and CEO and is a director of BioCardia, Inc., reported a transaction in the issuer's common stock on 08/11/2025 on Form 4. The filing shows 1,700 shares were disposed of under transaction code P.

The report lists a weighted-average sale price of $1.758 per share and states the individual trades ranged from $1.73 to $1.82. After the reported transaction, the reporting person’s direct beneficial ownership is shown as 167,562 shares. The filer notes they will provide a breakdown of the number of shares sold at each price upon request.

Insights

Securities/Fundamental Analyst

TL;DR: A routine insider sale of 1,700 shares reduces the CEO's direct stake to 167,562 shares; transaction appears immaterial.

The filing documents a sale of 1,700 common shares by Peter Altman at a weighted-average price of $1.758, with individual trades between $1.73 and $1.82. Relative to the post-transaction holding of 167,562 shares, the sale represents roughly a 1% reduction in his stake (approximately 1.0% of his prior holding). Transaction code P is recorded and the filer offers to provide per-trade price details on request. On these facts, the transaction is transparent and appears routine rather than material to company valuation.

Corporate Governance Expert

TL;DR: Insider disclosure is complete and transparent; the modest size suggests no immediate governance concern.

The Form 4 identifies Altman as both an officer (President and CEO) and a director, and reports a 1,700-share disposition leaving 167,562 shares beneficially owned. The filing includes a weighted-average price and a footnote promising full per-trade details upon request, which supports compliance with disclosure obligations. Given the small percentage change in ownership, this appears to be a routine liquidity action rather than a signal of governance or control issues.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CA 94085

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2025		P		1,700(1)	A	$1.758(1)	167,562	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $1.73 to $1.82 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ David McClung, by power of attorney	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did BioCardia (BCDA) insider Peter Altman report?

The Form 4 reports a disposition of 1,700 common shares by Peter Altman on 08/11/2025 recorded with transaction code P.

At what price were the shares sold in the BCDA Form 4?

The filing shows a weighted-average sale price of $1.758 per share and notes individual trades ranged from $1.73 to $1.82.

How many BioCardia shares does Peter Altman beneficially own after the reported trade?

After the reported transaction, the Form 4 shows Peter Altman directly beneficially owns 167,562 shares.

Does the filing provide a breakdown of the individual trades and prices?

The filing includes an explanatory footnote stating the transaction was executed in multiple trades and the filer will provide full information on the number of shares purchased at each price upon request.

What does transaction code 'P' indicate on this Form 4?

The Form 4 lists the transaction code as P for the reported disposition; the form does not include an in-line definition of the code in the provided content.